Journal article
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock, R de Wit, WR Berry, J Horti, A Pluzanska, KN Chi, S Oudard, C Theodore, ND James, I Turesson, MA Rosenthal, MA Eisenberger
NEW ENGLAND JOURNAL OF MEDICINE | MASSACHUSETTS MEDICAL SOC | Published : 2004
DOI: 10.1056/NEJMoa040720
Abstract
BACKGROUND: Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such treatment with docetaxel plus prednisone in men with this disease. METHODS: From March 2000 through June 2002, 1006 men with metastatic hormone-refractory prostate cancer received 5 mg of prednisone twice daily and were randomly assigned to receive 12 mg of mitoxantrone per square meter of body-surface area every three weeks, 75 mg of docetaxel per square meter every three weeks, or 30 mg of docetaxel per square meter weekly for five of every six weeks. The primary end point was overall survival. Se..
View full abstract